CC BY 4.0 · Indian J Med Paediatr Oncol 2023; 44(02): 229-240
DOI: 10.1055/s-0042-1760324
Review Article

Imaging Recommendations for Diagnosis, Staging, and Management of Esophageal Cancer

1   Department of Radiodiagnosis, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Tata Memorial Hospital, Mumbai, Maharashtra, India
,
2   Department of Radiodiagnosis, The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, United Kingdom
,
Prachi Patil
3   Department of Digestive Diseases and Clinical Nutrition, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Manoranjan Chowhan
4   Department of Nuclear Medicine and PET/CT, Aditya Birla Memorial Hospital, Pune, Maharashtra, India
,
Naveen Munmmudi
5   Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Devayani Niyogi
6   Department of Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Deepak Dabkara
7   Department of Oncology, CHL Hospitals, Indore, Madhya Pradesh, India
,
Suryaveer Singh
1   Department of Radiodiagnosis, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Ajaykumar Singh
8   Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Sanjana Devarmani
1   Department of Radiodiagnosis, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Varun Singh Dhull
4   Department of Nuclear Medicine and PET/CT, Aditya Birla Memorial Hospital, Pune, Maharashtra, India
,
Kumar Prabhash
8   Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Tata Memorial Hospital, Mumbai, Maharashtra, India
› Author Affiliations

Abstract

Early staging and treatment initiation affect prognosis of patients with esophageal and esophagogastric junction cancer; hence, it is imperative to have knowledge of proper choice of imaging modality for staging of these patients, to effectively convey relevant imaging findings to the treating physician/surgeon. It is also essential to be aware of pertinent imaging findings that need to be conveyed to the treating physician/surgeon at staging, and after treatment, including post-therapy complications (if any), so as to provide timely management to such patients. In this article, we have provided imaging guidelines for diagnosis, staging, post-therapy response evaluation, follow-up, and assessment of post-therapy complications of esophageal and esophagogastric junction cancer in a systematic manner. Besides, risk factors and clinical workup have also been elucidated. We have also attached comprehensive staging and post-therapy contrast-enhanced computed tomography and fluorodeoxyglucose-positron emission tomography/computed tomography-based synoptic reporting formats “ECI-RADS” and “pECI-RADS,” respectively, for esophageal and esophagogastric junction cancer in the supplement, for effective communication of imaging findings between a radiologist and the treating physician/surgeon.

Author's Contributions

Nivedita Chakrabarty was involved in conceptualization, designing, definition of intellectual content, literature search, manuscript preparation, manuscript editing Abhishek Mahajan was involved in manuscript editing and review. Kumar Prabhash, Prachi Patil, Manoranjan Chowhan, Naveen Munmmudi, Devayani Niyogi, Deepak Dabkara, Suryaveer Singh, Ajaykumar Singh, Sanjana Devarmani, and Varun Singh Dhull contributed to manuscript preparation.


Ethical Committee Clearance

Not required as patient data not revealed.




Publication History

Article published online:
10 February 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 
  • References

  • 1 Sung H, Ferlay J, Siegel RL. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
  • 2 Jayaprakasam VS, Yeh R, Ku GY. et al. Role of imaging in esophageal cancer management in 2020: update for radiologists. AJR Am J Roentgenol 2020; 215 (05) 1072-1084
  • 3 Kim TJ, Kim HY, Lee KW, Kim MS. Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy. Radiographics 2009; 29 (02) 403-421
  • 4 Rice TW, Patil DT, Blackstone EH. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg 2017; 6 (02) 119-130
  • 5 Daly JM, Fry WA, Little AG. et al. Esophageal cancer: results of an American College of Surgeons patient care evaluation study. J Am Coll Surg 2000; 190 (05) 562-572 , discussion 572–573
  • 6 Hoeben A, Polak J, Van De Voorde L, Hoebers F, Grabsch HI, de Vos-Geelen J. Cervical esophageal cancer: a gap in cancer knowledge. Ann Oncol 2016; 27 (09) 1664-1674
  • 7 Lee DJ, Harris A, Gillette A, Munoz L, Kashima H. Carcinoma of the cervical esophagus: diagnosis, management, and results. South Med J 1984; 77 (11) 1365-1367
  • 8 Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol 2015; 21 (26) 7933-7943
  • 9 Huang FL, Yu SJ. Esophageal cancer: Risk factors, genetic association, and treatment. Asian J Surg 2018; 41 (03) 210-215
  • 10 Watanabe M. Risk factors and molecular mechanisms of esophageal cancer: differences between the histologic subtypes. J Cancer Metastasis Treat 2015; 1: 1-7
  • 11 Choksi D, Kolhe KM, Ingle M. et al. Esophageal carcinoma: an epidemiological analysis and study of the time trends over the last 20 years from a single center in India. J Family Med Prim Care 2020; 9 (03) 1695-1699
  • 12 Sekar A, Rajendra A, Noronha V. et al. The epidemiological trend of esophageal cancer in Mumbai, India over the past two decades. Journal of Clinical Oncology 2021; 39 (15_suppl) e16095-e16095
  • 13 Accessed December 10, 2022, at: https://gco.iarc.fr/today/data/factsheets/populations/356-india-fact-sheets.pdf
  • 14 Accessed December 10, 2022, at: https://gco.iarc.fr/today/data/factsheets/cancers/6-Oesophagus-fact-sheet.pdf
  • 15 Accessed December 10, 2022, at: https://www.msdmanuals.com/en-in/professional/gastrointestinal-disorders/tumors-of-the-gastrointestinal-tract/esophageal-cancer
  • 16 Accessed December 10, 2022, at: https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf
  • 17 Lordick F, Mariette C, Haustermans K, Obermannová R, Arnold D. ESMO Guidelines Committee. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27 (suppl 5): v50-v57
  • 18 Accessed December 10, 2022, at: https://tmc.gov.in/ncg/docs/PDF/DraftGuidelines/ThoacicGuidelinesAndResearch/NCG_Esophageal_Cancer_Guidelines.pdf
  • 19 Accessed December 10, 2022, at: https://iria.org.in/oncologic-imaging-protocols-and-reporting-checklist/
  • 20 Accessed December 10, 2022, at: https://acsearch.acr.org/docs/69471/narrative/
  • 21 Elsherif SB, Andreou S, Virarkar M. et al. Role of precision imaging in esophageal cancer. J Thorac Dis 2020; 12 (09) 5159-5176
  • 22 Iyer R, Dubrow R. Imaging of esophageal cancer. Cancer Imaging 2004; 4 (02) 125-132
  • 23 Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003; 349 (23) 2241-2252
  • 24 Shah MA, Kennedy EB, Catenacci DV. et al. Treatment of locally advanced esophageal carcinoma: ASCO guideline. J Clin Oncol 2020; 38 (23) 2677-2694
  • 25 Convie L, Thompson RJ, Kennedy R, Clements WD, Carey PD, Kennedy JA. The current role of staging laparoscopy in oesophagogastric cancer. Ann R Coll Surg Engl 2015; 97 (02) 146-150
  • 26 Dhakras P, Uboha N, Horner V, Reinig E, Matkowskyj KA. Gastrointestinal cancers: current biomarkers in esophageal and gastric adenocarcinoma. Transl Gastroenterol Hepatol 2020; 5: 55
  • 27 DaVee T, Ajani JA, Lee JH. Is endoscopic ultrasound examination necessary in the management of esophageal cancer?. World J Gastroenterol 2017; 23 (05) 751-762
  • 28 Mannath J, Ragunath K. Role of endoscopy in early oesophageal cancer. Nat Rev Gastroenterol Hepatol 2016; 13 (12) 720-730
  • 29 Bang JY, Ramesh J, Hasan M. et al. Endoscopic ultrasonography is not required for staging malignant esophageal strictures that preclude the passage of a diagnostic gastroscope. Dig Endosc 2016; 28 (06) 650-656
  • 30 Erasmus JJ, Munden RF. The role of integrated computed tomography positron-emission tomography in esophageal cancer: staging and assessment of therapeutic response. Semin Radiat Oncol 2007; 17 (01) 29-37 s.
  • 31 Mamede M, Abreu-E-Lima P, Oliva MR, Nosé V, Mamon H, Gerbaudo VH. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results. Am J Clin Oncol 2007; 30 (04) 377-388
  • 32 Rustgi AK, El-Serag HB. Esophageal Carcinoma. New England Journal of Medicine 2014; 371 (26) 2499-2509
  • 33 Chen SH, Chan SC, Chao YK. et al. Detection of synchronous cancer by flurodeoxy glucose positron emission tomography/CT during primary staging work up for esophageal squamous cell carcinoma in Taiwan. PLoS One 2013; 8 (11) e82812
  • 34 Metzger JC, Wollschläger D, Miederer M. et al. Inclusion of PET-CT into planning of primary or neoadjuvant chemoradiotherapy of esophageal cancer improves prognosis. Strahlenther Onkol 2017; 193 (10) 791-799
  • 35 Zhong X, Yu J, Zhang B. et al. Using 18F-fluorodeoxyglucose positron emission tomography to estimate the length of gross tumor in patients with squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 2009; 73 (01) 136-141
  • 36 Lee G, Hoseok I, Seong-Jung K. et al. Clinical implication of PET-CT, MR in preoperative esophageal carcinoma staging compared with PETCT, EUS and CT. JNM 2014; 55 (08) 1242-1247
  • 37 Taniyama Y, Murakami K, Yoshida N. et al. Evaluating the effect of Neoadjuvant chemotherapy for esophageal cancer using the RECIST system with shorter-axis measurements: a retrospective multicenter study. BMC Cancer 2021; 21 (01) 1008 DOI: 10.1186/s12885-021-08747-y.
  • 38 Lee S, Choi Y, Park G. et al. 18F-FDG PET/CT parameters for predicting prognosis in esophageal cancer patients treated with concurrent chemoradiotherapy. Technol Cancer Res Treat 2021 Jan-Dec;20–15330338211024655
  • 39 Hodi FS, Ballinger M, Lyons B. et al. Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy. J Clin Oncol 2018; 36 (09) 850-858
  • 40 Chakrabarty N, Mahajan A, Baheti AD. et al. A radiologist's perspective on treatment-related pseudo progression: clues and hues. Indian J Med Paediatr Oncol 2022; 43 (01) 52-59
  • 41 Sudo K, Xiao L, Wadhwa R. et al. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol 2014; 32 (30) 3400-3405
  • 42 Malik S, Sharma G, Sanaka MR, Thota PN. Role of endoscopic therapy in early esophageal cancer. World J Gastroenterol 2018; 24 (35) 3965-3973 cited 2022Mar2 [Internet]
  • 43 Al-Batran SE, Homann N, Pauligk C. et al; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019;393(10184):1948–1957 cited 2022Feb11 [Internet]
  • 44 Allum WH, Bonavina L, Cassivi SD. et al. Surgical treatments for esophageal cancers. Ann N Y Acad Sci 2014; 1325 (01) 242-268 cited 2022Mar2 [Internet]
  • 45 Cancer E. Statistics | Cancer.Net [Internet]. [cited 2022 Mar 2]. Accessed December 10, 2022, at: Available from: https://www.cancer.net/cancer-types/esophageal-cancer/statistics
  • 46 Zeng C, Zhai T, Chen J. et al. Imaging biomarkers of contrast-enhanced computed tomography predict survival in oesophageal cancer after definitive concurrent chemoradiotherapy. Radiat Oncol 2021; 16 (01) 8
  • 47 Mantziari S, Pomoni A, Prior JO. et al. 18F- FDG PET/CT-derived parameters predict clinical stage and prognosis of esophageal cancer. BMC Med Imaging 2020; 20 (01) 7
  • 48 Park J-H, Kim KY, Song H-Y. et al. Radiation-induced esophageal strictures treated with fluoroscopic balloon dilation: clinical outcomes and factors influencing recurrence in 62 patients. Acta Radiol 2018; 59 (03) 313-321
  • 49 Chakrabarty N, Mahajan A. Esophageal cancer imaging - reporting and data system (ECI-RADS) and post-therapy ECI-RADS (pECI-RADS): Comprehensive synoptic reporting formats for esophageal cancer imaging: A narrative review. Cancer Research, Statistics, and Treatment 2022;5(03)